##  [Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis](/us-en/news/media-releases/novartis-announces-fda-advisory-committee-unanimously-recommends-approval-ain457-secukinumab-patients-moderate-severe-plaque-psoriasis-0 "Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis") 

  Oct 20, 2014